规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
H3 receptor ( Ki = 0.16 nM )
|
---|---|
体外研究 (In Vitro) |
Cinaciguat (10 μM) 显着增强细胞内 cGMP 的生成。Cinaciguat 对细胞收缩和诱导瞬时变化没有剂量依赖性影响[2]。
|
体内研究 (In Vivo) |
Cinaciguat (10 mg/kg/day,po) 处理糖尿病胆固醇不影响血压水平,但会导致水识别量降低。Cinaciguat 处理可减少糖尿病相关的氧化,预防 DM 相关的 NO-sGC-cGMP- PKG 信号改变改变,并减少 DM 相关的心肌肥大和细胞无菌[1]。 Cinaciguat (1-10-100 nM) 在 WT 和 apo-sGC 小鼠平滑肌条中均引起浓度收缩,但PGF2α对WT或apo-sGC的胃肠平滑肌条的相对活性无影响[3]。
|
动物实验 |
Rats are randomized into four groups after DM is confirmed: vehicle-treated control, cinaciguat-treated control, vehicle-treated diabetic, and cinaciguat-treated diabetic groups. Treatment begins immediately upon DM confirmation and lasts for 8 weeks. The animals are given either a 0.5% methylcellulose vehicle or the sGC activator cinaciguat in suspension p.o. (10 mg/kg/day). Daily water consumption is measured and water bottles are filled with the same volume of fresh tap water each morning. To avoid water spilling from the bottles, animal cages are handled carefully and are not moved after the bottles are replaced. Once every two days, the animals' body weight is measured, and the cinaciguat dosage is modified accordingly.
|
参考文献 |
|
分子式 |
C36H39NO5
|
---|---|
分子量 |
565.69856
|
精确质量 |
565.28
|
元素分析 |
C, 76.43; H, 6.95; N, 2.48; O, 14.14
|
CAS号 |
329773-35-5
|
相关CAS号 |
Cinaciguat hydrochloride; 646995-35-9
|
外观&性状 |
Solid powder
|
SMILES |
C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O
|
InChi Key |
WPYWMXNXEZFMAK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
|
化学名 |
4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
|
别名 |
BAY 582667; BAY-582667; BAY582667; BAY 58-2667; BAY-58-2667; BAY58-2667; Cinaciguat HCl; Cinaciguat hydrochloride
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~66 mg/mL (~198.6 mM)
Water: ~66 mg/mL Ethanol: ~66 mg/mL |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: 2.5 mg/mL (4.42 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7677 mL | 8.8386 mL | 17.6772 mL | |
5 mM | 0.3535 mL | 1.7677 mL | 3.5354 mL | |
10 mM | 0.1768 mL | 0.8839 mL | 1.7677 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00559650 | Terminated | Drug: Placebo Drug: Cinaciguat (BAY58-2667) |
Congestive Heart Failure | Bayer | December 2007 | Phase 2 |
NCT01067859 | Terminated | Drug: Placebo Drug: Cinaciguat (BAY58-2667) |
Acute Heart Failure | Bayer | March 2010 | Phase 2 |
NCT01064037 | Terminated | Drug: Placebo Drug: Cinaciguat (BAY58-2667) |
Heart Decompensation Heart Failure |
Bayer | April 2010 | Phase 2 |
NCT01065077 | Terminated | Drug: Placebo Drug: Cinaciguat (BAY58-2667) |
Acute Heart Failure | Bayer | March 2010 | Phase 2 |
Effect of diabetes mellitus (DM) and cinaciguat treatment on plasma and myocardial cyclic guanosine monophosphate (cGMP) content. Cardiovasc Diabetol . 2015 Oct 31:14:145. td> |
Cinaciguat treatment alleviates diabetes mellitus related oxidative stress. Cardiovasc Diabetol . 2015 Oct 31:14:145. td> |
The effect of diabetes mellitus and cinaciguat on myocardial NO-sGC-cGMP-PKG signalling. Cardiovasc Diabetol . 2015 Oct 31:14:145. td> |